By: Adam Feuerstein | 03/25/14 - 02:35 PM EDTA list that might be interesting only to me, but I will share anyway: The biotech and drug stocks getting hit the hardest during the biotech correction -- or whatever you want to call it:
Tops on the list is Geron (GERN), down 58% in March.
At No. 2: Ceres (CERE), an agriculturial biotech company, down 37%. I don't think anyone cares about Ceres. My apologies if you do.
A trio of stocks tied in third place: Xoma (XOMA), Cytrx (CYTR) and Celldex Therapeutics (CLDX) have all lost 39% of their value in March.
Cytrx's entanglement in a messy stock promotion scandal with the specter of an SEC investigation hovering of the stock easily explains the sell off. Xoma also issued some negative clinical data early in the month.
Celldex is a bit tougher to figure out.
08/14/14 - 10:20 AM EDT
08/13/14 - 12:04 PM EDT
08/12/14 - 05:11 PM EDT
08/12/14 - 07:17 AM EDT
08/11/14 - 05:29 PM EDT
08/20/14 - 10:17 AM EDT
08/20/14 - 09:50 AM EDT
08/20/14 - 09:35 AM EDT
08/19/14 - 16:23 PM EDT
08/19/14 - 12:00 PM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.